Pesonalised Risk Prediction For Severe Treatment-related Gastrointestinal Toxicity In Paediatric Cancer Patients Using Pre-treatment Gut Microbiome Analysis
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
The gut is home to trillions of good and bad bacteria, critical to human health. Each person has a different balance of bacteria, unique to their gut, which shapes their immune system and susceptibility to disease. I will investigate how the unique gut bacteria, in children with blood cancer, can be used to predict which children will develop severe gut side effects (diarrhoea) from their chemotherapy. This will identify high-risk children, enable personalised treatment and improve survival.
Thalassaemia is the most common blood disorder worldwide. In severe cases, life-long blood transfusions are needed to survive but complications including iron overload and bone disease can occur. Deferasirox, a drug used to treat iron overload has been linked to kidney stones and bone loss in these patients through increased loss of calcium in the urine. The purpose of this study is to investigate whether bone loss can be reversed by using a diuretic or an alternative iron chelator.
Patient Toxicity Prediction: Identification Of Mucosal Injury Mediators Using Microarray Technology
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
There is no effective way to identify all patients that will develop toxic side-effects during the course of their cancer treatment. Current pharmacogenetic testing is too narrow. This project aims to examine whole-genome profiles of patient blood to determine if risk markers of toxicity can be identified prior to beginning treatment. I will do this by comparing oesophageal cancer patients who go on to develop severe toxicity with those who only get mild treatment side-effects.